Studying safety and effectiveness of Poteligeo for certain skin lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is tracking the safety and effectiveness of a drug called Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome who have already tried at least one body-wide treatment. It is a post-market surveillance study, meaning the drug is already approved, and doctors are gathering real-world information about how well it works and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have a type of skin lymphoma called mycosis fungoides or Sézary syndrome.
- You have already tried at least one medicine that works throughout your body (systemic therapy) for this condition.
- You are not allergic to any of the ingredients in the study drug (mogamulizumab).
- You are not using the drug for a condition that is not approved.
- You have not received mogamulizumab in a previous clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called VG712 in patients with mycosis fungoides, a rare type of skin lymphoma that hasn't responded to previous treatments. The goal is to see if VG712 can shrink the cancer and improve quality of life.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This trial tests whether a special light treatment done outside the body (extracorporeal photopheresis) can help people with Sezary syndrome. It is meant to see if the treatment is safe and effective for this specific type and stage of skin lymphoma.
This trial tests a new drug called DT-7012 for people with a type of skin lymphoma (mycosis fungoides or Sezary syndrome) that has come back or not responded to at least two prior treatments. The goal is to find a safe dose and see if it shrinks the lymphoma.
This trial tests a cream applied to the skin that may help control early-stage mycosis fungoides, a type of skin lymphoma. It aims to see if the cream can reduce symptoms and slow disease progression without the need for stronger treatments.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.